RALEIGH, N.C.--(BUSINESS WIRE)--Merz Americas announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for XEOMIN ® ...
RESEARCH TRIANGLE PARK – Raleigh-based Merz North America has received approval from the U.S. Food and Drug Administration to market a treatment for blepharospasm, or involuntary blinking, in adults.
You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. An error has occurred. Please try again ...
Blepharospasm is a condition that is characterized by involuntary movements of the eyelids. Tics and twitches around the eye area are common, but in severe cases this can inhibit the ability of an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback